Multaq (Dronedarone HCl) Patent Expiration, LOE Window & CMS Spending

Multaq (Dronedarone HCl) by Sanofi: FDA Orange Book LOE 2031-06-30, 0 AB generics, $427.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSanofi
FDA Application & PathwayN022425 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-06-30
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$427.1M
2024 Medicare Part D Spend$414.8M
2024 Medicaid Spend$12.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.